| Literature DB >> 34868345 |
Kunyao Zhu1, Man Zhang1, Jia Long2, Shuqi Zhang3, Huali Luo3.
Abstract
Using network pharmacology and molecular docking, this study investigated the molecular mechanisms by which the active components in Salvia miltiorrhiza can alleviate acute pancreatitis. Initially, the active components of Salvia miltiorrhiza and the targets collected from the GeneCards database were screened based on the platform of systematic pharmacology analysis of traditional Chinese medicine. Subsequently, the active components were intersected with the disease targets. Also, interactions among the targets were computed using the STRING database. Biological function and pathway enrichment were analyzed using the Cluster Profiler package in the R software. Protein-protein interaction and component target pathway network were constructed using the Cytoscape software. Ultimately, the key targets and their corresponding components in the network were verified using the AutoDock Vina software. The results showed Salvia miltiorrhiza had 111 targets for acute pancreatitis. The biological process (BP) analysis showed that the active components of Salvia miltiorrhiza induced a drug response, positive regulation of transcription by RNA polymerase II promoter, signal transduction, positive regulation of cell proliferation, and negative regulation of apoptosis. Furthermore, the KEGG enrichment analysis screened 118 (P < 0.05) signaling pathways, such as the pathways related to cancer, neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, and cAMP signaling pathway, to name a few. Finally, molecular docking showed that the active components of Salvia miltiorrhiza had a good binding affinity with their corresponding target proteins. Through network pharmacology, this study predicted the potential pharmacodynamic material basis and the mechanisms by which Salvia miltiorrhiza can treat acute pancreatitis. Moreover, this study provided a scientific basis for mining the pharmacodynamic components of Salvia miltiorrhiza and expanding the scope of its clinical use.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34868345 PMCID: PMC8635895 DOI: 10.1155/2021/8323661
Source DB: PubMed Journal: Comput Math Methods Med ISSN: 1748-670X Impact factor: 2.238
Information of the databases, analysis platform, and software.
| Name | Website | Version |
|---|---|---|
| TCMSP |
| / |
| UniProt |
| / |
| GeneCards |
| / |
| STRING |
| / |
| Cytoscape |
| 3.8.0 |
| Venny |
| / |
| DAVID |
| / |
| R-project |
| 4.0.3 |
| PDB |
| / |
| MGLTools |
| 1.5.6 |
| PyMoL |
| 1.7.2.1 |
| AutoDock Vina |
| 1.1.2 |
Information of the candidate components of Salvia miltiorrhiza.
| MOl ID | Molecule Name | OB(%) | DL | Herb | |
|---|---|---|---|---|---|
| 1 | MOL001601 | 1,2,5,6-tetrahydrotanshinone | 38.75 | 0.36 | SM |
| 2 | MOL001659 | Poriferasterol | 43.83 | 0.76 | SM |
| 3 | MOL001771 | poriferast-5-en-3beta-ol | 36.91 | 0.75 | SM |
| 4 | MOL001942 | isoimperatorin | 45.46 | 0.23 | SM |
| 5 | MOL002222 | sugiol | 36.11 | 0.28 | SM |
| 6 | MOL002651 | Dehydrotanshinone II A | 43.76 | 0.4 | SM |
| 7 | MOL002776 | Baicalin | 40.12 | 0.75 | SM |
| 8 | MOL000569 | digallate | 61.85 | 0.26 | SM |
| 9 | MOL000006 | luteolin | 36.16 | 0.25 | SM |
| 10 | MOL006824 |
| 39.51 | 0.76 | SM |
| 11 | MOL007036 | 5,6-dihydroxy-7-isopropyl-1,1-dimethyl-2,3-dihydrophenanthren-4-one | 33.77 | 0.29 | SM |
| 12 | MOL007041 | 2-isopropyl-8-methylphenanthrene-3,4-dione | 40.86 | 0.23 | SM |
| 13 | MOL007045 | 3 | 44.93 | 0.44 | SM |
| 14 | MOL007048 | (E)-3-[2-(3,4-dihydroxyphenyl)-7-hydroxy-benzofuran-4-yl]acrylic acid | 48.24 | 0.31 | SM |
| 15 | MOL007049 | 4-methylenemiltirone | 34.35 | 0.23 | SM |
| 16 | MOL007050 | 2-(4-hydroxy-3-methoxyphenyl)-5-(3-hydroxypropyl)-7-methoxy-3-benzofurancarboxaldehyde | 62.78 | 0.4 | SM |
| 17 | MOL007051 | 6-o-syringyl-8-o-acetyl shanzhiside methyl ester | 46.69 | 0.71 | SM |
| 18 | MOL007058 | formyltanshinone | 73.44 | 0.42 | SM |
| 19 | MOL007059 | 2-beta-Hydroxymethyllenetanshiquinone | 32.16 | 0.41 | SM |
| 20 | MOL007061 | Methylenetanshinquinone | 37.07 | 0.36 | SM |
| 21 | MOL007063 | przewalskin a | 37.11 | 0.65 | SM |
| 22 | MOL007064 | przewalskin b | 110.32 | 0.44 | SM |
| 23 | MOL007068 | Przewaquinone B | 62.24 | 0.41 | SM |
| 24 | MOL007069 | przewaquinone c | 55.74 | 0.4 | SM |
| 25 | MOL007070 | (6S,7R)-6,7-dihydroxy-1,6-dimethyl-8,9-dihydro-7H-naphtho[8,7-g]benzofuran-10,11-dione | 41.31 | 0.45 | SM |
| 26 | MOL007071 | przewaquinone f | 40.31 | 0.46 | SM |
| 27 | MOL007077 | sclareol | 43.67 | 0.21 | SM |
| 28 | MOL007079 | tanshinaldehyde | 52.47 | 0.45 | SM |
| 29 | MOL007081 | Danshenol B | 57.95 | 0.56 | SM |
| 30 | MOL007082 | Danshenol A | 56.97 | 0.52 | SM |
| 31 | MOL007085 | Salvilenone | 30.38 | 0.38 | SM |
| 32 | MOL007088 | cryptotanshinone | 52.34 | 0.4 | SM |
| 33 | MOL007093 | dan-shexinkum d | 38.88 | 0.55 | SM |
| 34 | MOL007094 | danshenspiroketallactone | 50.43 | 0.31 | SM |
| 35 | MOL007098 | deoxyneocryptotanshinone | 49.4 | 0.29 | SM |
| 36 | MOL007100 | dihydrotanshinlactone | 38.68 | 0.32 | SM |
| 37 | MOL007101 | dihydrotanshinoneI | 45.04 | 0.36 | SM |
| 38 | MOL007105 | epidanshenspiroketallactone | 68.27 | 0.31 | SM |
| 39 | MOL007107 | C09092 | 36.07 | 0.25 | SM |
| 40 | MOL007108 | isocryptotanshi-none | 54.98 | 0.39 | SM |
| 41 | MOL007111 | Isotanshinone II | 49.92 | 0.4 | SM |
| 42 | MOL007115 | manool | 45.04 | 0.2 | SM |
| 43 | MOL007118 | microstegiol | 39.61 | 0.28 | SM |
| 44 | MOL007119 | miltionone I | 49.68 | 0.32 | SM |
| 45 | MOL007120 | miltionone II | 71.03 | 0.44 | SM |
| 46 | MOL007121 | miltipolone | 36.56 | 0.37 | SM |
| 47 | MOL007122 | Miltirone | 38.76 | 0.25 | SM |
| 48 | MOL007123 | miltirone II | 44.95 | 0.24 | SM |
| 49 | MOL007124 | neocryptotanshinone ii | 39.46 | 0.23 | SM |
| 50 | MOL007125 | neocryptotanshinone | 52.49 | 0.32 | SM |
| 51 | MOL007127 | 1-methyl-8,9-dihydro-7H-naphtho[5,6-g]benzofuran-6,10,11-trione | 34.72 | 0.37 | SM |
| 52 | MOL007130 | prolithospermic acid | 64.37 | 0.31 | SM |
| 53 | MOL007132 | (2R)-3-(3,4-dihydroxyphenyl)-2-[(Z)-3-(3,4-dihydroxyphenyl)acryloyl]oxy-propionic acid | 109.38 | 0.35 | SM |
| 54 | MOL007140 | (Z)-3-[2-[(E)-2-(3,4-dihydroxyphenyl)vinyl]-3,4-dihydroxy-phenyl]acrylic acid | 88.54 | 0.26 | SM |
| 55 | MOL007141 | salvianolic acid g | 45.56 | 0.61 | SM |
| 56 | MOL007142 | salvianolic acid j | 43.38 | 0.72 | SM |
| 57 | MOL007143 | salvilenone I | 32.43 | 0.23 | SM |
| 58 | MOL007145 | salviolone | 31.72 | 0.24 | SM |
| 59 | MOL007149 | NSC 122421 | 34.49 | 0.28 | SM |
| 60 | MOL007150 | (6S)-6-hydroxy-1-methyl-6-methylol-8,9-dihydro-7H-naphtho[8,7-g]benzofuran-10,11-quinone | 75.39 | 0.46 | SM |
| 61 | MOL007151 | Tanshindiol B | 42.67 | 0.45 | SM |
| 62 | MOL007152 | Przewaquinone E | 42.85 | 0.45 | SM |
| 63 | MOL007154 | tanshinone iia | 49.89 | 0.4 | SM |
| 64 | MOL007155 | (6S)-6-(hydroxymethyl)-1,6-dimethyl-8,9-dihydro-7H-naphtho[8,7-g]benzofuran-10,11-dione | 65.26 | 0.45 | SM |
| 65 | MOL007156 | tanshinone VI | 45.64 | 0.3 | SM |
Figure 1The component-target network of SM.
Figure 2Venn map of “Danshen” target and acute pancreatitis target. Note: the blue part represents the target genes of acute pancreatitis, the red part represents the target genes of the active components of Salvia miltiorrhiza to be modified, and the intersection represents the common target genes.
Figure 3The analysis diagram of target-protein interaction network.
Figure 4GO functional enrichment analysis: Bubble diagram of the analysis of the biological processes.
Figure 5GO functional enrichment analysis: Bubble diagram of the analysis of the cell components.
Figure 6GO functional enrichment analysis: Bubble diagram of the analysis of the molecular functions.
Figure 7GO functional enrichment analysis: histogram of the analysis of the biological processes.
Figure 8GO functional enrichment analysis: cellular components analysis.
Figure 9GO functional enrichment analysis: histogram of the analysis of the molecular functions.
Figure 10Bubble diagram of the KEGG pathway enrichment analysis.
Figure 11Histogram of the KEGG pathway enrichment analysis.
The information of the top 20 pathways in the KEGG pathway enrichment analysis.
| No. | Pathway | Gene |
| Gene count |
|---|---|---|---|---|
| 1 | hsa05200: pathways in cancer | RB1, GSK3B, CDKN1A, GSTP1, PTGS2, ADCY8, RELA, EGFR, PIK3CG, CASP9, EDNRA, RXRA, CCND1, MYC, CASP3, ERBB2, AKT1, MAPK1, PRKACA, JUN, HSP90AA1, NOS2, MMP1, MMP2, STAT3, FOS, MMP9, VEGFA, NFKBIA, AR, IL6, CDK4, CDK2, BCL2, MDM2, BIRC5, PPARG, MET, TP53, BCL2L1 | 7.57E-20 | 44 |
| 2 | hsa04080: neuroactive ligand-receptor interaction | CHRM2, OPRD1, CHRM3, PRSS1, CHRM1, CHRNA2, CHRM4, CHRNA7, CHRM5, HTR2C, ADRA1D, ADRB2, HTR2A, ADRA1B, NR3C1, ADRA1A, EDNRA, CALCR, DRD1, GABRE, DRD2, DRD5, GABRA2, GABRA1, GABRA6, GABRA5, HTR1A, HTR1B, OPRM1, ADRA2C, F2, GABRG3, ADRA2B, ADRA2A | 3.64E-19 | 34 |
| 3 | hsa05161: hepatitis B | RB1, CDKN1A, JUN, PCNA, STAT3, FOS, TNF, MMP9, PIK3CG, RELA, CASP9, NFKBIA, CCNA2, IL6, CCND1, CDK4, MYC, CASP3, CDK2, BCL2, BIRC5, AKT1, MAPK1, TP53 | 3.15E-16 | 24 |
| 4 | hsa05219: bladder cancer | RB1, CDKN1A, MMP1, MMP2, MMP9, EGFR, VEGFA, CCND1, CDK4, MYC, ERBB2, MDM2, MAPK1, TP53 | 1.04E-13 | 14 |
| 5 | hsa05215: prostate cancer | RB1, GSK3B, CDKN1A, HSP90AA1, EGFR, PIK3CG, RELA, CASP9, NFKBIA, AR, CCND1, ERBB2, CDK2, MDM2, BCL2, AKT1, MAPK1, TP53 | 1.17E-13 | 18 |
| 6 | hsa04151: PI3K-Akt signaling pathway | CHRM2, GSK3B, CDKN1A, CHRM1, ITGB3, RELA, EGFR, PIK3CG, CASP9, RXRA, CCND1, MYC, AKT1, MAPK1, MCL1, HSP90AA1, NOS3, INSR, IL2, VEGFA, IL4, IL6, CDK4, CDK2, BCL2, MDM2, MET, TP53, BCL2L1 | 5.55E-12 | 29 |
| 7 | hsa04066: HIF-1 signaling pathway | CDKN1A, EDN1, NOS2, NOS3, INSR, STAT3, EGFR, PIK3CG, RELA, VEGFA, IL6, IFNG, ERBB2, BCL2, AKT1, HMOX1, MAPK1 | 7.13E-12 | 17 |
| 8 | hsa05222: small cell lung cancer | RB1, NOS2, PTGS2, PIK3CG, RELA, CASP9, NFKBIA, RXRA, CCND1, CDK4, MYC, CDK2, BCL2, AKT1, TP53, BCL2L1 | 1.43E-11 | 16 |
| 9 | hsa05212: pancreatic cancer | RB1, STAT3, EGFR, PIK3CG, RELA, VEGFA, CASP9, CCND1, CDK4, ERBB2, AKT1, MAPK1, TP53, BCL2L1 | 6.79E-11 | 14 |
| 10 | hsa05210: colorectal cancer | GSK3B, JUN, FOS, PIK3CG, CASP9, CCND1, MYC, CASP3, BCL2, BIRC5, AKT1, MAPK1, TP53 | 5.73E-10 | 13 |
| 11 | hsa04024: cAMP signaling pathway | CHRM2, JUN, CHRM1, HTR1A, HTR1B, FOS, ADRB2, ADCY8, PIK3CG, RELA, NFKBIA, EDNRA, CAMK4, PDE3A, AKT1, MAPK1, DRD1, DRD2, PRKACA, DRD5 | 1.36E-09 | 20 |
| 12 | hsa04915: estrogen signaling pathway | JUN, HSP90AA1, NOS3, MMP2, FOS, OPRM1, ADCY8, ESR1, MMP9, EGFR, PIK3CG, ESR2, AKT1, MAPK1, PRKACA | 1.53E-09 | 15 |
| 13 | hsa04725: cholinergic synapse | CHRM2, ACHE, CHRM3, CHRM1, CHRM4, CHRNA7, CHRM5, FOS, ADCY8, PIK3CG, CAMK4, BCL2, AKT1, MAPK1, PRKACA | 7.09E-09 | 15 |
| 14 | hsa04068: foxo signaling pathway | IL10, CDKN1A, INSR, STAT3, SLC2A4, MAPK14, EGFR, PIK3CG, IL6, CCNB1, CCND1, CDK2, MDM2, AKT1, MAPK1 | 8.18E-08 | 15 |
| 15 | hsa04931: insulin resistance | NFKBIA, GSK3B, PTPN1, IL6, NOS3, INSR, STAT3, AKT1, SLC2A4, TNF, RELA, PIK3CG | 2.80E-06 | 12 |
| 16 | hsa04726: serotonergic synapse | CASP3, HTR1A, HTR1B, MAPK1, HTR2C, HTR3A, HTR2A, PRKACA, PTGS2, SLC6A4, PTGS1 | 2.42E-05 | 11 |
| 17 | hsa05216: thyroid cancer | RXRA, CCND1, MYC, MAPK1, PPARG, TP53 | 1.36E-04 | 6 |
| 18 | hsa04932: nonalcoholic fatty liver disease | GSK3B, IL6, CASP7, JUN, RXRA, CASP3, INSR, AKT1, TNF, RELA, PIK3CG | 3.24E-04 | 11 |
| 19 | hsa04152: AMPK signaling pathway | CCNA2, CCND1, FASN, INSR, AKT1, PPARG, SLC2A4, ADRA1A, PIK3CG | 0.001461352 | 9 |
| 20 | hsa05204: chemical carcinogenesis | CHRNA7, GSTP1, CYP1A2, CYP1A1, CYP3A4, PTGS2 | 0.013489355 | 7 |
Figure 12Component-target pathway network of Salvia miltiorrhiza.
Docking results for the core components of Salvia miltiorrhiza and key target proteins.
| Affinity (kcal/mol) | |||||||
|---|---|---|---|---|---|---|---|
| Target | Original ligands | Isocryptotan-shinone | Dihydrosalvian-olone | Salvia miltiorrhiza new quinone D | Tanshinone IIA | Salviol ketone | Luteolin |
| PTGS2 (5ikv) | -9.08 | -9.82 | -9.23 | -10.54 | -10.06 | -9.26 | -8.25 |
| OPRM1 (6ddf) | -2.47 | -7.81 | -8.05 | -7.74 | -8.73 | -8.65 | -7.38 |
| NCOA1 (5nma) | -9.98 | -9.40 | -8.51 | -9.36 | -9.50 | -8.26 | -7.42 |
| CHRM1 (6oij) | -5.24 | -8.42 | -7.24 | -9.06 | -8.05 | -7.55 | -7.00 |
Figure 13Schematic diagram of molecular docking between core components of Salvia miltiorrhiza and key targets. Note: (a)–(d) are molecular docking diagrams of Salvia miltiorrhiza new quinone D and PTGS2, Salvia miltiorrhiza new quinone D and CHRM1, tanshinone IIA and NCOA1, and tanshinone IIA and OPRM1, respectively.